- Home
- ACIU vs EVC Comparison
ACIU vs EVC Comparison
Compare ACIU & EVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- EVC
- Stock Information
- Founded
- ACIU 2003
- EVC 1996
- Country
- ACIU Switzerland
- EVC United States
- Employees
- ACIU N/A
- EVC N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- EVC Broadcasting
- Sector
- ACIU Health Care
- EVC Industrials
- Exchange
- ACIU Nasdaq
- EVC Nasdaq
- Market Cap
- ACIU 173.7M
- EVC 171.0M
- IPO Year
- ACIU 2016
- EVC 2000
- Fundamental
- Price
- ACIU $1.69
- EVC $1.92
- Analyst Decision
- ACIU Strong Buy
- EVC
- Analyst Count
- ACIU 2
- EVC 0
- Target Price
- ACIU $10.00
- EVC N/A
- AVG Volume (30 Days)
- ACIU 137.1K
- EVC 175.1K
- Earning Date
- ACIU 04-30-2025
- EVC 05-08-2025
- Dividend Yield
- ACIU N/A
- EVC 10.53%
- EPS Growth
- ACIU N/A
- EVC N/A
- EPS
- ACIU N/A
- EVC N/A
- Revenue
- ACIU $32,014,254.00
- EVC $364,948,000.00
- Revenue This Year
- ACIU N/A
- EVC $64.06
- Revenue Next Year
- ACIU $676.94
- EVC N/A
- P/E Ratio
- ACIU N/A
- EVC N/A
- Revenue Growth
- ACIU 91.20
- EVC 22.86
- 52 Week Low
- ACIU $1.43
- EVC $1.58
- 52 Week High
- ACIU $4.98
- EVC $2.73
- Technical
- Relative Strength Index (RSI)
- ACIU 46.75
- EVC 51.67
- Support Level
- ACIU $1.55
- EVC $1.76
- Resistance Level
- ACIU $1.79
- EVC $1.97
- Average True Range (ATR)
- ACIU 0.10
- EVC 0.08
- MACD
- ACIU 0.03
- EVC 0.01
- Stochastic Oscillator
- ACIU 66.67
- EVC 72.00
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About EVC Entravision Communications Corporation
Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the Media segment. Geographically, the company generates the majority of its revenue from the United States.